#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pulmonary sarcoidosis Acute graft versus host disease in liver Glomerulonephritis Leukoencephalopathy Cataract Cholangitis sclerosing Multifocal motor neuropathy Prostate cancer Follicular lymphoma stage I Acute lymphocytic leukaemia Antithrombin III deficiency Transplant rejection Endocrine ophthalmopathy Vascular malformation Breast cancer metastatic More trials…

    Learn about Rare Diseases

    Atypical teratoid/rhabdoid tumour of CNS – Life with Disease SAPHO syndrome – Diagnostics Retinitis pigmentosa – Diagnostics Gaucher’s disease type III – Trials in Disease Glycogen storage disease type II – Diagnostics Nodal marginal zone B-cell lymphoma – Trials in Disease Kearns-Sayre syndrome Small intestine leiomyosarcoma – Trials in Disease Phenylketonuria Angiosarcoma non-metastatic – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Iclepertin Potato Starch Doxycycline Metformin Embonate Lasmiditan Glofitamab Atomoxetine Bupropion Hydrochloride Tazobactam Immunoglobulin A Gentamicin Sulfate Dolutegravir Remdesivir Dextromethadone Hydrochloride Istaroxime Eletriptan ENSIFENTRINE Messenger Rna Encoding Cas9 Cefalexin Monohydrate Opevesostat Tosilate More therapies…

    Learn about Your Condition

    Neurofibrosarcoma Solitary fibrous tumour Osteochondrodysplasia Huntington's disease Parkinson's disease Toxic epidermal necrolysis Patent ductus arteriosus Uterine leiomyosarcoma Drug eruption Choroidal neovascularisation Arthritis infective Embolic stroke Ebola disease Langerhans' cell histiocytosis Leukaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Type 1 diabetes mellitus

  • Study on the Safety and Feasibility of Diamyd (Glutamate Decarboxylase 2) for Individuals Aged 8-17 at Risk for Type 1 Diabetes with HLA DR3-DQ2 Haplotype

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Type 1 diabetes mellitus
    Investigated Drugs:
    • Glutamate Decarboxylase 2, Human, Recombinant
    Sweden

  • Study on the Effects of Alendronate on Bone and Blood Sugar Markers in Patients with Diabetes and Osteopenia/Osteoporosis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Osteopenia
    • Type 1 diabetes mellitus
    • Osteoporosis
    Investigated Drugs:
    • Alendronate Sodium Monohydrate
    Denmark

  • Study on the Safety and Effectiveness of Diamyd and Colecalciferol for Adolescents and Adults with Recently Diagnosed Type 1 Diabetes

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Glutamate Decarboxylase 2, Human, Recombinant
    • Colecalciferol
    Czechia Estonia Germany Hungary The Netherlands Poland +2

  • Study on the Effects of Siplizumab in Adults with New Onset Type 1 Diabetes

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Type 1 diabetes mellitus
    Investigated Drugs:
    • Siplizumab
    • Cetirizine Dihydrochloride
    • Paracetamol
    Belgium Italy Spain Sweden

  • Study on Colchicine for Reducing Inflammation in Patients with Type 1 Diabetes

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Type 1 diabetes mellitus
    Investigated Drugs:
    • Colchicine
    Denmark

  • Study on Glucagon and Insulin for Improving Insulin Absorption in Patients with Type 1 Diabetes

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Type 1 diabetes mellitus
    Investigated Drugs:
    • Glucagon
    Norway
Previous Page
1 … 4 5 6 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!